GSK Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BN7SWP63
GBP
19.25
0.73 (3.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

6.15 M

Shareholding (Sep 2025)

FII

0.13%

Held by 7 FIIs

DII

99.87%

Held by 1 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 75,905 Million ()

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

260.63%

stock-summary
Debt Equity

1.08

stock-summary
Return on Equity

43.25%

stock-summary
Price to Book

4.70

Revenue and Profits:
Net Sales:
7,986 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,646 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.96%
0%
7.96%
6 Months
31.62%
0%
31.62%
1 Year
37.3%
0%
37.3%
2 Years
25.18%
0%
25.18%
3 Years
36.23%
0%
36.23%
4 Years
15.89%
0%
15.89%
5 Years
41.86%
0%
41.86%

GSK Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-1.25%
EBIT Growth (5y)
1.22%
EBIT to Interest (avg)
8.50
Debt to EBITDA (avg)
1.63
Net Debt to Equity (avg)
0.99
Sales to Capital Employed (avg)
0.82
Tax Ratio
13.89%
Dividend Payout Ratio
96.58%
Pledged Shares
0
Institutional Holding
0.13%
ROCE (avg)
24.07%
ROE (avg)
54.88%

Valuation key factors

Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
4.67
EV to EBIT
15.21
EV to EBITDA
8.98
EV to Capital Employed
2.90
EV to Sales
2.62
PEG Ratio
NA
Dividend Yield
280.34%
ROCE (Latest)
19.09%
ROE (Latest)
35.15%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 7 Foreign Institutions (0.13%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 6.25% vs -7.40% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.11% vs 253.69% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,986.00",
          "val2": "7,516.00",
          "chgp": "6.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,873.00",
          "val2": "2,962.00",
          "chgp": "-3.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "184.00",
          "val2": "162.00",
          "chgp": "13.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-57.00",
          "val2": "-92.00",
          "chgp": "38.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,646.00",
          "val2": "1,772.00",
          "chgp": "-7.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "214.60%",
          "val2": "284.60%",
          "chgp": "-7.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 3.46% vs 3.42% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -44.40% vs 7.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31,376.00",
          "val2": "30,328.00",
          "chgp": "3.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8,213.00",
          "val2": "9,287.00",
          "chgp": "-11.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "644.00",
          "val2": "775.00",
          "chgp": "-16.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2,469.00",
          "val2": "-1,430.00",
          "chgp": "-72.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,951.00",
          "val2": "5,308.00",
          "chgp": "-44.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "180.50%",
          "val2": "230.60%",
          "chgp": "-5.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary

Jun'25
Mar'25
Change(%)
Net Sales
7,986.00
7,516.00
6.25%
Operating Profit (PBDIT) excl Other Income
2,873.00
2,962.00
-3.00%
Interest
184.00
162.00
13.58%
Exceptional Items
-57.00
-92.00
38.04%
Consolidate Net Profit
1,646.00
1,772.00
-7.11%
Operating Profit Margin (Excl OI)
214.60%
284.60%
-7.00%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 6.25% vs -7.40% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -7.11% vs 253.69% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
31,376.00
30,328.00
3.46%
Operating Profit (PBDIT) excl Other Income
8,213.00
9,287.00
-11.56%
Interest
644.00
775.00
-16.90%
Exceptional Items
-2,469.00
-1,430.00
-72.66%
Consolidate Net Profit
2,951.00
5,308.00
-44.40%
Operating Profit Margin (Excl OI)
180.50%
230.60%
-5.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 3.46% vs 3.42% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -44.40% vs 7.86% in Dec 2023

stock-summaryCompany CV
About GSK Plc stock-summary
stock-summary
GSK Plc
Pharmaceuticals & Biotechnology
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Company Coordinates stock-summary
Company Details
G S K House, 980 Great West Road , BRENTFORD None : TW8 9GS
stock-summary
Tel: 44 20 80475000
stock-summary
Registrar Details